|Articles|October 17, 2022

People and Business News —10/22

People

Alliance Pharma expanded their leadership team by four, bringing on board a new Chief Operating Officer in Jean Pierre Boutrand, Chief Commercial Officer in Vito Saccente, Chief Financial Officer in Glenn Weber, and Susan Woolley as Chief People Officer.

Paradigm Clinical Research announced the appointment of Kurt Mussina as CEO. Additonally, the company announced growth on its executive leadership team, bringing on board Travis Milnes as chief financial officer and Amy Henderson as head of clinical operations.

Sharp, has appointed Robert Feltz as Director, Analytical and Formulation Services and Michael MacNeir as Vice President, Global Business Development.

Trialbee announced the addition of Jo Holton as VP of Global Sales to their company.

TransCelerate announced that, previously COO, Janice Chang, has been appointed Chief Executive Officer.

Business

Recbio Technology Co. contracted OCT Clinical to carry out its phase III clinical study for a SARS-CoV-2 vaccine.

Stayble Therapeutics and OCT Clinical reported that the last patient has been enrolled in the ongoing phase IIb clinical trial of STA363.

dMed |Clinipace announced that it is changing its corporate name to Caidya (pronounced KAY-dee-uh).

Recognition

CluePoints celebrated its tenth anniversary.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

October 22nd, 2026

Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect

In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.

October 22nd, 2026

ACT Brief: Applied Clinical Trials at 2026 SCRS Global Site Solutions Summit

In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.

© putilov_denis - © putilov_denis - stock.adobe.com

October 21st, 2026

Obesity Is More Than Weight: Practical Approaches to Managing Comorbidities in Clinical Research

Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.

October 21st, 2026

What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight

In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.

A new Syneos Health-Optum partnership aims to make trial timelines and costs more predictable. Credit: Stock.Adobe.com/wladimir1804

October 20th, 2026

Syneos Health, Optum Partner on Adaptive Clinical Development Model

Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.

Deidentified real-world data, project-by-project review and an Abu Dhabi hypertension program anchor an early-stage AstraZeneca-Oracle AI collaboration. Credit: Stock.Adobe.com/Konstantin Yuganov

October 20th, 2026

AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring

What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.

October 20th, 2026

Where AI Governance in Clinical Development Falls Short

In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.